Мyasthenia gravis and pregnancy: overview of the problem

June 29, 2023
УДК:  616.74+616.8]-009.17:618.2/.3]-036-07-08

Taking into account the fairly widespread prevalence of myasthenia among women and the fact that myasthenia does not affect fertility, the possibility of manifestation of the disease in reproductive age cannot be excluded. This necessitates the study of the clinical course of myasthenia during pregnancy and the provision of adequate attention to an adequate selection of therapy. The article presents epidemiological and etiological data, illustrates and describes key aspects of pathogenesis of myasthenia. The patterns of manifestation of myasthenia during pregnancy and the effect of the disease on the course of pregnancy are given. The dependence of the severity of symptoms of myasthenia on the trimester of pregnancy is analyzed. Emphasis is placed on the relationship of the presented patterns with the immunological characteristics of the woman’s body in different periods of pregnancy, these features are also considered in the postpartum period. The specificity of the process of childbirth in women with myasthenia is described, the probability of spontaneous termination of pregnancy, the occurrence of difficulties during childbirth and the possibility of identifying and patterns in the formation of transient neonatal myasthenia of the fetus are considered.The issue of the safety of spinal and epidural anesthesia in the process of delivery is raised. Mandatory diagnostic procedures for making a diagnosis of myasthenia during pregnancy are highlighted. Emphasis is placed on the role of the importance of analyzing the methods of treatment of this disease, and also presents the results of studies devoted to the study of this problem. The role of thymectomy and the effect of this surgical method of treatment on the course of the disease in terms of pregnancy are indicated. It has been shown that predicting the manifestation of the disease during pregnancy is difficult, however, the pregnancy can be completed safely and, most importantly, myasthenia itself is not an absolute contraindication to pregnancy.


1. Hong Y., Zisimopoulou P., Trakas N. et al. (2017) Multiple antibody detection in ‘seronegative’ myasthenia gravis patients. Eur. J. Neurol., 24(6): 844–850. doi.org/10.1111/ene.13300.

2. Yan M., Xing G.-L., Xiong W.-C., Mei L. (2018) Agrin and LRP4 antibodies as new biomarkers of myasthenia gravis. Ann. New York Acad. of Sci., 1413(1): 126–135. doi.org/10.1111/nyas.13573.

3. Carr A.S., Cardwell C.R., McCarron P.O., McConville J. (2010) A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol., 10(1): doi.org/10.1186/1471-2377-10-46.

4. Kalidindi M., Ganpot S., Tahmesebi F. et al. (2007) Myasthenia Gravis and pregnancy. J. Obstetr. Gynaecol., 27(1): 30–32. doi.org/10.1080/01443610601016842.

5. Berrih-Aknin S., Frenkian-Cuvelier M., Eymard B. (2014) Diagnostic and clinical classification of autoimmune myasthenia gravis. J. Autoimmun., 48–49: 143–148. doi.org/10.1016/j.jaut.2014.01.003.

6. Renton A.E., Pliner H.A., Provenzano C. et al. (2015) A genome-wide association study of Myasthenia Gravis. JAMA Neurol., 72(4): 396. doi.org/10.1001/jamaneurol.2014.4103.

7. Ciafaloni E., Massey J.M. (2004) Myasthenia Gravis and pregnancy. Neurol. Clin., 22(4): 771–782. doi.org/10.1016/j.ncl.2004.06.003.

8. Braga A.C., Pinto C., Santos E., Braga J. (2016) Myasthenia gravis in pregnancy: Experience of a Portuguese center. Muscle Nerve, 54(4): 715–720. doi.org/10.1002/mus.25095.

9. Ducci R.D., Lorenzoni P.J., Kay C.S.K. et al. (2017) Clinical follow-up of pregnancy in myasthenia gravis patients. Neuromuscul. Dis., 27(4): 352–357. doi.org/10.1016/j.nmd.2017.01.021.

10. Wen J.-C., Liu T.-C., Chen Y.-H. et al. (2009) No increased risk of adverse pregnancy outcomes for women with myasthenia gravis: A nationwide population-based study. Eur. J. Neurol., 16(8): 889–894. doi.org/10.1111/j.1468-1331.2009.02689.x.

11. Varner M. (2013) Myasthenia Gravis and pregnancy. Clin. Obstetr. Gynecol., 56(2): 372–381. doi.org/10.1097/grf.0b013e31828e92c0.

12. Shimizu Y., Kitagawa K. (2016) Management of myasthenia gravis in pregnancy. Clin. Experiment. Neuroimmunol., 7(2): 199–204. doi.org/10.1111/cen3.12305.

13. Hoff M.J., Midelfart A. (2015) Maternal myasthenia gravis: A cause for arthrogryposis multiplex congenita. J. Child. Orthopaed., 9(6): 433–435. doi.org/10.1007/s11832-015-0690-8.

14. Hamel J., Ciafaloni E. (2018) An update. Neurol. Clin., 36(2): 355–365. doi.org/10.1016/j.ncl.2018.01.005.

15. Sanders D.B., Wolfe G.I., Benatar M. et al. (2016) International consensus guidance for management of Myasthenia Gravis. Neurol., 87(4): 419–425. doi.org/10.1212/wnl.0000000000002790.

16. Durst J.K., Rampersad R.M. (2015) Pregnancy in women with solid-organ transplants. Obstet. Gynecol. Surv., 70(6): 408–418. doi.org/10.1097/ogx.0000000000000194.

17. Leroy C., Rigot J.-M., Leroy M. et al. (2015) Immunosuppressive drugs and fertility. Orphanet J. Rare Dis., 10(1): doi.org/10.1186/s13023-015-0332-8.

18. Götestam Skorpen C., Hoeltzenbein M., Tincani A. et al. (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann. Rheumat. Dis., 75(5): 795–810. doi.org/10.1136/annrheumdis-2015-208840.

19. Constantinescu S., Pai A., Coscia L.A. et al. (2014) Breast-feeding after transplantation. Best Pract. Res. Clin. Obstetr. Gynaecol., 28(8): 1163–1173. doi.org/10.1016/j.bpobgyn.2014.09.001.

20. Stieglbauer K., Pichler R., Topakian R. (2017) 10-year-outcomes after rituximab for myasthenia gravis: Efficacy, safety, costs of inhospital care, and impact on childbearing potential. J. Neurol. Sci., 375: 241–244. doi.org/10.1016/j.jns.2017.02.009.

21. Feasby T., Banwell B., Benstead T. et al. (2007) Guidelines on the use of intravenous immune globulin for neurologic conditions. Transf. Med. Rev., 21. doi.org/10.1016/j.tmrv.2007.01.002.

22. Marson P., Gervasi M. T., Tison T. et al. (2015) Therapeutic apheresis in pregnancy: General considerations and current practice. Transf. Apher. Sci., 53(3): 256–261. doi.org/10.1016/j.transci.2015.11.004.

23. Marx A., Pfister F., Schalke B. et al. (2013) The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun. Rev., 12(9): 875–884. doi.org/10.1016/j.autrev.2013.03.007.

24. Wolfe G.I., Kaminski H.J., Aban I.B. et al. (2016) Randomized trial of thymectomy in myasthenia gravis. New Engl. J. Med., 375(6): 511–522. doi.org/10.1056/nejmoa1602489.

25. Norwood F., Dhanjal M., Hill M. et al. (2013) Myasthenia in pregnancy: Best practice guidelines from a UK Multispecialty Working Group. J. Neurol. Neurosurg. Psychiatr., 85(5): 538–543. doi.org/10.1136/jnnp-2013-305572.